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Objective: To study the clinical and molecular characteristics of a sample of Brazilian patients with Congenital
Hyperinsulinemic Hypoglycemia (CHH).
Methods: Electronic message was sent to members from Endocrinology Department- Brazilian Society of Pediatrics
requesting clinical data for all cases of CHH. A whole blood sample from living patients was requested for DNA extraction
followed by a search for mutations of the genes ABCC8, KCNJ11, GCK, GLUD1, HADH, SLC16A1 and HNF4A.
Results: Of the 61 patients evaluated, 36 (59%) were boys, and only 16 (26%) were born by normal delivery.
Gestational age ranged from 32 to 41 weeks (mean = 37 weeks and 6 days). Birth weight ranged from 1590 to
5250 g (mean = 3430 g). Macrossomia occurred in 14 cases (28%). Age at diagnosis ranged from 1 to 1080 days
(mean = 75 days). DNA for molecular analysis was obtained from 53 of the 61 patients. Molecular changes in the
ABCC8 gene were detected in 15 (28%) of these 53 cases, and mutations in the KCNJ11 gene were detected in 6
(11%). Mutations in the GLUD1 gene were detected in 9 cases (17%) of the total series. Mutations of the GCK
gene in heterozygosis were detected in 3 cases. No mutations were detected in the sequencing of genes HADH,
SLC16A1 and HNF4A.
Conclusion: The present study conducted in Brazil permitted the collaborative compilation of an important
number of CHH cases and showed that the present clinical and molecular data are similar to those of published
global series.
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The maintenance of appropriate blood glucose levels is
of vital importance at all ages, but particularly during
the neonatal and breastfeeding period. In this phase of
life, cerebral tissue is not yet fully mature and is marked
by intense metabolic activity and extreme avidity for
glucose, being considerably more sensitive to reductions
of glycemic levels even if transient. Thus, the occurrence
of hypoglycemia in this phase of life is relate to high
morbility and mortality [1-4].* Correspondence: rliberatore@fmrp.usp.br
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article, unless otherwise stated.Inappropriate insulin secretion in relation to blood
glucose levels characterizes hyperinsulinism, which is
the main cause of persistent and recurrent hypoglycemia
during this phase of life [1,5,6].
The congenital hyperinsulinemic hypoglycemia (CHH)
represent a heterogeneous group of clinical condition,
the most severe and frequent form of HH [6-8]. The
CHH may present as different clinical characteristics
(responsive or not to diazoxide, elevated or not ammonia
levels) and histological subgroups (focal or diffuse form),
but the aspect most recently investigated is the genetic of
CHH [1-10].
Mutations in seven different genes (ABCC8, KCNJ11,
GLUD1, GCK, HADH, SLC16A1 and HNF4A) are
responsible for about 50% of all CHH cases [1,2]. OfMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Blood glucose, insulin levels and glucose infusion
rate (GIR) in 61 patients with CHH
Glucose (mg/dL) Insulin (IU/mL) GIR (mg/kg/min)
5-77* 2.5-147* 10-41*
28.5 ± 4.7** 24.9 ± 11.3** 17.2 ± 5.5**
*Range **Median and Standard Deviation.
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neighboring chromosome 11 (11p15.1), are responsible
for the expression of the proteins SUR1 and Kir6.2.
These proteins comprise the potassium channels sensitive
to adenosine-triphosphate which play a fundamental role
in the control of insulin secretion stimulated by glucose.
Inactivating mutations in these two genes are responsible
for the most common and severe forms of CHH [9-18].
Defects of the other five genes involved are responsible for
a smaller number of cases of CHH [1,2].
Mutations in these genes are expressed with particular
histopathological features, clinical manifestations, thera-
peutic response to drugs and therefore the investigation
of these molecular alterations permits a precise diagnosis
and an appropriate management.
The objectives of the present study were to obtain
clinical information regarding patients with CHH from
the largest possible number of clinical centers in Brazil
and to determine the molecular etiology of such cases.
Patients and methods
An electronic message was sent to all members of the
Department of Endocrinology of the Brazilian Society of
Pediatrics, involving representatives of almost all Brazilian
states, inviting them to participate in this study. Informa-
tion about all patients with a diagnosis of CHH was
requested, such as sex, gestational age, type of delivery,
birth weight and length, age at the onset of symptoms, age
at diagnosis of the disease, laboratory results, histological
form of the disease, response to drug therapy, need of pan-
createctomy, presence of sequelae, and mortality.
The study was approved by the Human Research Ethics
Committee of the Faculty of Medicine of Ribeirão Preto,
University of São Paulo, and the parents or persons
responsible for the living patients gave written informed
consent to participate. A whole blood sample was then
collected from each index case and his/her parents for
DNA extraction followed by the determination of muta-
tions of the seven genes.
DNA was extracted from peripheral blood leukocytes
using a commercial kit (QIAamp DNA Mini Kit-Qiagen,
Dusseldorf, German) and the sample was stored at −70°C;
the exon ligands of the intron/exons of the genes were
amplified by PCR. The PCR product was then sequenced
by a standard method using an ABI 3730 sequencer
(Applied Bio systems, Warrington, UK) and the sequences
obtained were compared to the published sequences [4-9].
Mutations were first searched in the ABCC8 and
KCNJ11 genes. When no mutations were detected in
these genes, mutations were searched in the GLUD1 and
GCK genes and in cases of no mutations, the remaining
genes were investigated.
Data are reported as absolute and relative frequency,
with means and standard deviations.Results
Data and blood samples of 61 children with CHH were
obtained. Blood samples were also obtained from the
parents of most of these children, for a total of 140
samples.
Most samples were from the Southeast region of Brazil,
which concentrates the largest number of pediatric endo-
crinology centers. However, the Center-West, Northeast
and South regions were also represented. The North
region did not send samples.
Of the 61 patients evaluated, 36 (59%) were boys. Gesta-
tional age ranged from 32 to 41 weeks (mean = 37 and
6 days; SD = 5 days). Birth weight ranged from 1590
to 5250 g (mean = 3430 g; SD = 480 g). Macrossomia
occurred in 14 cases (28%). Birth length was available for
42 patients, but this result was excluded because it was
found to be unreliable.
Age at diagnosis ranged from 1 to 1080 days (mean =
75 days; SD = 17 days), with a diagnosis being made at
more than 90 days of life in 14 (28%) patients.
The diagnosis of HH are suspect by the need of high
rate of glucose infusion to maintain normal blood glu-
cose level, and confirmed by the dosage of low blood
glucose level, inadequate insulin level, low ketones and
free fatty acids levels in serum [1,2,19]. Other laboratory
tests should de collected at the same time with glucose,
insulin, ketones and free fatty acids, as ammonia, lactate
and glucagon stimulation test for the diagnostic work-
out. Except for the glucose and insulin, not all the
laboratory tests were carried out for all patients. Blood
lactate level was done in 27, ammonia level in 19, ketone
level in 17 and free fatty acids in 16 patients. Table 1 lists
the results of blood glucose, insulin levels and glucose
infusion rate (GIR, mg/kg/min).
The initial drug used as treatment was glucorticoid in
40 cases (65%). Treatment with diazoxide failure in 24
patients (40%), who were later, submitted to pancreatec-
tomy. All patients submitted to pancreatectomy presented
the histological pattern, performed at the different centers,
of the diffuse form of the disease.
Table 2 presents the type of treatment performed and
the distribution per patient.
DNA quantity and quality sufficient for molecular ana-
lysis was obtained from 53 of the 61 patients (87%). In 15
of these 53 cases (28%), molecular changes were detected
in the ABCC8 gene. All mutations were in heterozygosis,
Table 2 Type of drug used as treatment for 61 patients with CHH
Diazoxide Glucorticoid Octreotide GH* Nifedipine Glucagon
41 cases 40 cases 24 cases 14 cases 3 cases 3 cases
67% 66% 39% 23% 5% 5%
*Growth Hormone.
Table 3 Mutations found in 61 patients with CHH
Gene Exon Mutation Number of patients
ABCC8 1 c.72C > A 4
c.134C > T 2
2 c.257 T > G 1
3 c.331G > A 1
4 c.563A > G 1
5 c.742C > T 1
12 c.1792C > T 1
31 c.3992-9G > A 2
36 c.4415-13G > A 2
KCNJ11 c.801C > G 2
c.808C > G 2
2 c.1142G > A. 2
GLUD1 6 c.37266C > T 1
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T in 2), in exons 31 (c.3992-9G >A) and 36 (c.4415-13G >
A) in 2 cases, and in exons 2 (c.257 T >G), 3 (c.331G >A),
4 (c.563A >G), 5 (c.742C >T) and 12 (c.1792C >T) in 1.
Mutations in the KCNJ11 gene were detected in 6
cases (11%), all of them in heterozygosis, 2 of them
being c.801C > G, 2 c.808C > G and 2 c.1142G > A.
The ABCC8 and KCNJ11 genes were jointly responsible
for mutation in 21 (39%) of 53 cases of CHH.
Analysis of the GLUD1 gene was carried out in the 32
cases in which no mutations were detected in the
ABCC8 and KCNJ11 genes. Mutations in this gene were
detected in 9 cases (17%), 8 of them being in heterozy-
gosis and 1 in homozygosis. Of these, 7 cases occurred
in exon 7 (c.1019A > G), 1 in exon 6 (c.37266C > T) and
1 in exon 10 (c.49322G > T). Serum ammonia was deter-
mined in only one of these 9 patients, with a normal
result.
Mutations of the GLUD1 gene were detected in 17%
of the total series and in 29% of the cases in which no
mutations were detected for the ABCC8 and KCNJ11
genes.
The GCK gene was analyzed in the 23 cases in which
no mutation was detected in the ABCC8, KCNJ11 and
GLUD1 genes. Mutations in heterozygosis were detected
in this gene in 3 cases (6%), 2 of them in exon 6
(c.1115C > T) and 1 in exon 10 (c.1829G > T). The GCK
gene was responsible for 6% of the mutations in the total
series and for 10% of the mutations detected in cases
that were negative for mutations of the genes associated
with the potassium channel.
Sequencing of the HADH, SLC16A1 and HNF4A genes
did not reveal any mutations.
Table 3 and Figure 1 show the distribution of muta-
tions by gene and also their percentages in the group.
The clinical-molecular correlation with the response
to diazoxide and with the histological form could not be
determined because in 68% of the cases in which diazoxide
was used the dose administered was less than 5 mg/kg/d,
not considered ideal for the establishment of the response.
All those patients that used low dose, didn’t respond to
medical treatment.7 c.1019A > G 7
10 c.49322G > T 1
GCK 6 c.1115C > T 2
10 c.1829G > T 1Discussion
This was the first large-scale study compiling CHH cases
in Brazil. Although most samples were from the Southeastregion of the country, all regions were represented, except
for the North.
The sample was quite representative in global terms. Re-
cent publications have reported 17 cases for Saudi Arabia
[20], 11 cases for China and 33 cases for Italy [21].
The largest samples have been compiled in the two major
world reference centers, i.e., England (Great Ormond Hos-
pital) with 300 cases [22] and the United States (Children’s
Hospital of Philadelphia) with 417 cases [23] and 223 cases
of pancreatectomy [24].
As observed in other series, we also could not detect
differences regarding gender and prematurity [20-23].
Birth weight ranged from 1590 to 5250 g, with a mean
value of 3430 g. In the present series, macrossomia
occurred in 14 cases (28%) as compared to 50% of cases
in the Italian sample [21]. The diagnosis was made after
90 days of life in 14 (28%) in our children, later than
other series, which is a matter of concern since a delayed
diagnosis increases the risk of morbi-mortality.
There is still a substantial heterogeneity regarding the
diagnostic threshold for the diagnosis of hypoglycemia
in Brazil. Regarding the collection of the diagnostic crit-
ical sample, there was no standardization of the exams
Figure 1 Distribution by gene of the mutations found in 61 patients with CHH.
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was rarely determined, and it should be remembered that
hyperammonemia directs the clinical and molecular diag-
nosis and the clinical conduct regarding the GLUD1 gene.
There is also a clear need to standardize the treatment,
also considering that diazoxide is not a drug easily available
in Brazil, requiring importation.
Diazoxide is the medication of choice for the treat-
ment of hypoglycemia due to hyperinsulinism during the
neonatal period. None of the other studies have reported
the systematic and early use of glucorticoids, as noted in
the present series. Nifedipine is not indicated and the
use of growth hormone is indicated only in the presence
of its deficiency [25-27].
The lack of response to treatment occurred in 40% of
the present cases, a much higher rate than reported in
the more recent literature [20-24]. Surgery was possibly
indicated before the correct use of drug treatment, with
appropriate doses. It was interesting to note that only 2
of the most recent 11 cases required pancreatectomy.
It is noteworthy that 100% of the operated cases had
the diffuse form of the disease. According to the litera-
ture, 1/3 of the operated cases involve the focal form of
the disease [22-24] and this difference requires revision
of the histological material and clinical-molecular
correlation.
Together, genes ABCC8 and KCNJ11 were respon-
sible for mutations in 21 of 53 cases (39%) of CHH.
This result is similar to obtained in other series, i.e.,
47% of cases in the American series [22] and 40.8% in
the British one [23].
A clinical-molecular correlation regarding the response
to diazoxide and the histological form was found to be
impossible.
Thus, mutations of the GLUD1 gene were detected
in 17% of the total series and in 29% of cases in whichno mutations of the ABCC8 and KCNJ11 genes were
detected. As reported earlier, this gene is responsible
for the clinical form of hypoglycemia associated with
high levels of serum ammonia, and is also the major
gene affected in cases in which no mutations are
detected in genes ABCC8 and KCNJ11 [28-31]. Serum
ammonia was determined in only one of these patients,
with a normal result. A high level of serum ammonia
directs the molecular investigation and the drug treat-
ment, as the response to diazoxide is usually exuberant,
with no low dose. Unfortunately, diazoxide was not used
in these 9 cases, a fact that did not permit us to establish
the clinical-molecular relationship reported in the litera-
ture [19,28,32-34].
This result has been observed in large series, with the
mutations of this gene being as frequent as those of the
genes of the potassium channel in the forms responsive
to diazoxide [28-31].
The molecular changes in gene GCK accounted for 6%
of the mutations detected in the entire series and for
10% of the mutations detected in the cases that were
negative for mutations in the genes associated with the
potassium channel, in agreement with previous literature
data [35-38].
In general, mutations were detected in 63% of the
series, most of them occurring in the two genes cod-
ing for the proteins SUR 1 and Kir6.2, responsible for
the functioning of the ATP-dependent potassium
channel [39].
Thus, the present pioneering study conducted in Brazil
permitted the collaborative compilation of an important
number of CHH cases from almost all regions of the
country, showing that our clinical and molecular data
are similar to those for large global series and underscor-
ing the need to standardize the diagnosis and treatment
of CHH in our country.
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CHH: Congenital Hyperinsulinemic Hypoglycemia.
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